Singapore cell therapy hub to deliver products for world
SCG Cell Therapy plans to establish Singapore as its international hub for cell therapy research, manufacturing and clinical development to deliver products across Asia Pacific, the USA, Europe and the world.
In line with this, the biotech company has signed an agreement with the Cell Therapy Facility of Singapore Health Sciences Authority (HSA-CTF) for the evaluation and validation of SCG’s proprietary cell therapy manufacturing process to develop a new treatment option for patients with hepatitis B virus-related hepatocellular carcinoma.
"Singapore is an attractive location to set up an international hub"The process validation will be performed in the Good Manufacturing Practice (GMP)-certified facility at HSA-CTF. SCG Cell Therapy will use the validation result to support global Investigational New Drug Application of SCG101 – autologous T-cell receptor T cell therapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze